

REMARKS


Claims 1-11, 13 and 15-33 are presented herein for examination. Various claims have been amended above, primarily for eliminating multiple dependencies and placing the subject matter in better condition for U.S. examination. These amendments have not been made in view of the prior art. The specification has been amended to reflect the priority of the application. Claims 12 and 14 have been canceled as they are directed to non-statutory subject matter. Claims 16-33 are newly added.

Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted on accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice. Examination on the merits is respectfully requested, as is entry of this amendment prior to calculation of the filing fee.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

Date: April 21, 2005


Robert J. Smith
Reg. No. 40,820
Attorney for Applicants

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Direct Phone (919)483-9616
Facsimile (919)483-7988